Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer

Inoue,Yasuhiro; Hiro,Junichiro; Toiyama,Yuji; Tanaka,Koji; Mohri,Yasuhiko; Kusunoki,Masato

doi:10.3892/ol.2011.508

Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer

Authors:
- Yasuhiro Inoue
- Junichiro Hiro
- Yuji Toiyama
- Koji Tanaka
- Yasuhiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Mie, Japan
Published online on: December 1, 2011 https://doi.org/10.3892/ol.2011.508
Pages: 363-368

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of advanced colorectal cancer (CRC) increasingly requires a multimodality approach, which adds to the complexity of clinical decision-making. This study investigates the optimal use of current chemotherapy in multimodality therapy for advanced CRC. We enrolled 208 patients with unresectable primary and metastatic (recurrent) CRC who underwent chemotherapy in our hospital. Radiofrequency ablation and/or secondary surgery were used depending on tumor response to chemotherapy. Disease sites varied among patients and included unresectable liver, lung and peritoneal metastasis. Chemotherapy produced cytoreduction in 71 of 208 patients (34%). Multimodality cytoreduction increased overall survival to a median of 46.0 months vs. 20.2 months with chemotherapy alone (P<0.0001). The response rate to chemotherapy was independently associated with cytoreduction. Molecular targeted therapy reduced the number of tumor cells sooner than conventional chemotherapy, and correlated with repeated cytoreduction that further prolonged survival. Aggressive chemotherapy as initial treatment for advanced CRC leads to cytoreduction and is associated with extended survival in patients receiving multimodality therapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Ries LA, Wingo PA, Miller DS, et al: The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 88:2398–2424. 2000.
3	Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
4	Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 25:1670–1676. 2007.
5	Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
6	Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
7	Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
8	Regnard JF, Grunenwald D, Spaggiari L, et al: Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 66:214–219. 1998. View Article : Google Scholar : PubMed/NCBI
9	Ballantyne GH and Quin J: Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 71:4252–4266. 1993. View Article : Google Scholar : PubMed/NCBI
10	Headrick JR, Miller DL, Nagorney DM, et al: Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 71:975–980. 2001. View Article : Google Scholar : PubMed/NCBI
11	Stang A, Fischbach R, Teichmann W, Bokemeyer C and Braumann D: A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 45:1748–1756. 2009. View Article : Google Scholar : PubMed/NCBI
12	Nikfarjam M, Shereef S, Kimchi ET, et al: Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol. 16:1860–1867. 2009. View Article : Google Scholar : PubMed/NCBI
13	Inoue Y, Miki C, Hiro J, et al: Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: a preliminary study. Oncol Rep. 14:1571–1576. 2005.PubMed/NCBI
14	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
15	Kusunoki M, Yanagi H, Noda M, et al: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer. 89:1228–1235. 2000. View Article : Google Scholar
16	Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
17	Inoue Y, Miki C and Kusunoki M: Current directions in chemotherapy for colorectal cancer. J Gastroenterol. 41:821–831. 2006. View Article : Google Scholar : PubMed/NCBI
18	Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 16:1311–1319. 2005. View Article : Google Scholar
19	Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11:38–47. 2010. View Article : Google Scholar